GSK-971086

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H12F6N4O
Molecular Weight	450.3366
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=CC2=C(C=CC(C#N)=C2C(F)(F)F)N1CC3=NOC(=N3)C4=CC=CC(=C4)C(F)(F)F

InChI

InChIKey=ZEDODTZELVBHTG-UHFFFAOYSA-N

InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C21H12F6N4O
Molecular Weight	450.3366
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical
Record UNII	8TFL50092H
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

GSK-971086

Common Name

English

2-METHYL-4-(TRIFLUOROMETHYL)-1-((5-(3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-3-YL)METHYL)INDOLE-5-CARBONITRILE

Systematic Name

English

GSK-971086A

Code

English

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

86620664

PRIMARY

CAS

1018971-95-3

PRIMARY

FDA UNII

8TFL50092H

PRIMARY

CLINICAL_TRIALS.GOV

GSK-971086

PRIMARY

Official Title: A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers; Purpose: This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses.

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					EJC4C3UYXH

ANDROGEN RECEPTOR

TARGET -> AGONIST

Comments:

SARM

Amount:

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					8TFL50092H

GSK-971086

ACTIVE MOIETY

Comments:

Originator: GlaxoSmithKline; Mechanism of Action: Androgen receptor modulator; Highest Development Phase: No development reported for Muscular atrophy; Most Recent Event: 29 Apr 2011 No development reported - Phase-I for Muscular atrophy in USA (unspecified route)

Amount:

Showing 1 to 1 of 1 entries

Previous1Next